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COMMENTARY
Impact of funding influenza vaccination on coverage among Australian children: a
national study using MedicineInsight, a large general practice database
Carla De Oliveira Bernardo a, David Alejandro González-Chica a,b, and Nigel Stocks a,c,d
aDiscipline of General Practice, Adelaide Medical School, The University of Adelaide, Adelaide, Australia; bAdelaide Rural Clinical School, The
University of Adelaide, Adelaide, Australia; cAustralian Partnership for Preparedness Research on Infectious Disease Emergencies (APPRISE) Centre
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ABSTRACT
Influenza contributes to morbidity and mortality worldwide. Children are at a higher risk of influenza-
related complications and vaccination promotes direct protection and limits transmission. This study
aimed to explore influenza vaccination coverage among children in Australian general practice from
2015 to 2018, and patterns in coverage before and after the implementation of state-funded immuniza-
tion programs. Data from 196,520 ‘active’ patients (3+ consultations in two consecutive years) aged
<5 years from 542 Australian general practices were included (MedicineInsight database). Logistic
regression models were used to identify associations between vaccination with patient and practice
characteristics. The overall vaccination coverage increased more than five times from 2015 (3.9%) to
2018 (19.6%) and varied among states. Children attending practices located in the wealthiest areas were
more likely to receive the vaccine and appeared to benefit most from the funding, as the increase in
coverage from 2017 to 2018 was greater among them than those attending practices in the least
advantaged areas (17 vs. 11 percentage points, respectively). This relationship was not evident when
analyzing the patient’s socioeconomic level. In conclusion, free influenza vaccinations increase coverage
in at-risk populations. Promotional campaigns may be required to maintain higher coverage and target
practices located in low-income areas.
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Influenza is a highly contagious viral respiratory infection that
contributes to morbidity and mortality especially among chil-
dren aged < 5 years, the elderly, pregnant women and people
with chronic conditions.1–3 The economic consequences of
influenza in children are extensive, involving both direct (e.g.
hospitalizations) and indirect costs (e.g. productivity losses for
their parents).4,5 Global estimates have found that up to 105,000
influenza-associated respiratory deaths occur annually among
children aged < 5 years.6 In Australia, the highest rates of
laboratory-confirmed influenza and influenza hospitalization
from 2006 to 2015 were in this age group.7
Vaccination is the most important measure to prevent influ-
enza infection and influenza-related hospitalization and death.1,4
Studies show that influenza vaccination in children is either cost-
saving or cost-effective, as they are also the principal transmitters
of influenza.4,8–11 The World Health Organization includes all
children aged six months to < 5 years as a priority group to be
targeted for annual vaccination.3 Although some countries are
following this recommendation, such as the United States
(US),12 Canada,13 Brazil,14 Malta15 and Australia,16 there is still
a high number of countries recommending the vaccine for
children in restricted age groups (e.g. 6 months-2 years; 2–-
3 years; 2–4 years).15 Furthermore, funding or payment methods
vary across countries. In Europe, only 40% of countries reporting
a recommendation for influenza vaccination in children offered
the vaccine at no cost through national health services.15 In
Australia, until 2017, only Western Australia had funded the
vaccine for all children aged 6 months to < 5 years, but from
2018 all states and territories have provided free influenza vac-
cine for this group, except for Northern Territory which started
in 2019.17
Identifying influenza vaccination coverage and understand-
ing what factors are associated with that is essential when trying
to develop effective vaccine strategies and reduce influenza-
related outcomes. It is therefore unfortunate that influenza vac-
cination is not required to be routinely recorded on the
Australian Immunization Register (AIR), even those adminis-
tered in children, and unlike other childhood vaccines, there are
no incentive payments for immunization providers to report this
information.18 For this reason and other issues with the record-
ing process,19 influenza vaccination is expected to be under-
reported to the AIR. An Australian study showed that almost
70% of influenza vaccinations administered in a sample of chil-
dren with special riskmedical conditions between 2014 and 2015
were not recorded in the AIR.20 However, other sources of
primary care data, including MedicineInsight, a large general
practice database, have shown good data quality21 and consis-
tency in estimating influenza vaccination coverage in adults22
and could be used for the same purpose in children. Therefore,
CONTACT Carla De Oliveira Bernardo carla.bernardo@adelaide.edu.au Discipline of General Practice, The University of Adelaide, Helen Mayo North Building
(Frome Road), Level 1, Room N113.02, Adelaide, SA 5005, Australia.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
2020, VOL. 16, NO. 3, 630–635
https://doi.org/10.1080/21645515.2019.1664866
© 2019 The Author(s). Published with license by Taylor & Francis Group, LLC.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
this study aimed to identify influenza vaccination coverage
among children aged < 5 years from 2015 to 2018 in
Australian general practice using the MedicineInsight database,
and patterns in coverage before and after the implementation of
state-funded programs that provided free influenza vaccinations
to this age group.
Patients and methods
Sample
This study used data from the MedicineInsight database,
a national general practice program developed and managed
by the National Prescribing Service (NPS) MedicineWise.1
De-identified clinical information system data is extracted reg-
ularly from participating general practices around Australia.
Details of data collection are available elsewhere.21–23
To investigate influenza immunization coverage from 2015 to
2018, ‘active’ patients aged <5 years were included for analysis.
‘Active’ patients were defined according to the Royal Australian
College of General Practitioners as any person who has at least
three consultations in two consecutive years in a single general
practice.24
Data extraction
When a child is vaccinated in an Australian general practice,
general practitioners (GPs) and registered nurses may select
a medical code in the medical record system or type a ‘free’
text to register this procedure. ‘Free’ text records can include
synonyms of influenza vaccination (i.e. flu shot or flu injection)
as well as brand names. The data extraction process was based on
a previous algorithm used to identify influenza vaccination
among adults in the MedicineInsight database.22 Therefore, the
terms used to identify all recorded influenza vaccinations in the
immunization field included the term ‘flu’, brand names avail-
able in Australia during the study period, such as Agrippal®,
Fluarix®, FluQuadri®, Influvac®, Vaxigrip®, as well as possible
misspellings of these words.
Outcome and covariates
Influenza immunization status for each year from 2015 to
2018 for ‘active’ patients aged < 5 years was used to provide
annual vaccination coverage among all ‘active’ patients in this
age group who had a consultation that year.
Covariates comprise practice and patient’s characteristics.
Practice characteristics include state, rurality (major cities;
inner regional; outer regional/remote/very remote) and
Index of Relative Socio-economic Advantage and
Disadvantage (IRSAD) quintile according to practice loca-
tion. IRSAD is a macroeconomic indicator of relative eco-
nomic and social advantage/disadvantage position within an
area compared with the rest of the country.25 Patient’s vari-
ables include gender, ethnicity (Aboriginal and/or Torres
Strait Islander: yes/no), IRSAD quintile according to the
location of residence, and the presence of some comorbid-
ities requiring influenza immunization (i.e. diabetes, cardiac
disease or severe asthma).16 Different fields of the
MedicineInsight database were used in for the identification
of these comorbidities, including diagnosis, reason for
encounter or prescription. Severe asthma was defined as
those patients with a diagnosis of asthma requiring the use
of prednisolone.22,26
Data analysis
Influenza vaccination coverage from 2015 to 2018 was
calculated as the adjusted proportion of ‘active’ patients
aged < 5 years vaccinated that year among all active
patients in the same age group who had a consultation
that year. The association between influenza vaccine cover-
age and practice or patient’s characteristics was assessed
using logistic regression with robust standard errors for
taking into account the clustering of patients within the
practice. Analyses investigating associations with patient’s
characteristics were adjusted for gender and practice vari-
ables, while associations with practice characteristics were
mutually adjusted. Marginal adjusted prediction of vaccina-
tion coverage in each category of the exposure variables was
then estimated and presented in a table and graphically
with their respective 95% confidence intervals.
All analyses were performed in the statistical software Stata
15.0 (StataCorp, Texas, USA). To minimize selection bias (i.e.
the likelihood of receiving medical treatments or diagnosis
increase with the number of visits to the practice)27 analyses
were conditioned to the inverse of the patient’s probability of
being in the sample (1/median number of consultations with
the GP). The independent MedicineInsight Data Governance
Committee has approved the study (protocol 2017–007) and
the Human Research Ethics Committee of the University of
Adelaide exempted it of an ethical review, as only non-
identifiable data was used.
Results
The number of ‘active’ patients varied from 72,252 in 2015, to
81,648 in 2016, 96,282 in 2017 and 119,806 in 2018 (Table 1).
Approximately 67% of practices were located in major cities,
30% of them in areas in the top IRSAD quintile and 15% in
the bottom quintile. Around 52% of patients were boys, 4.5%
were Aboriginal or Torres Strait Islander and 5% had
comorbidity.
Overall, vaccination coverage was similar in 2015 and
2016 (3.9%), with a slight increase in 2017 (5.1%).
However, the coverage in 2018 was four times higher
(19.6%) than in previous years, and this pattern was
observed in all states except the Northern Territory and
Western Australia. Patients from practices located in the
highest IRSAD quintiles were more likely to receive the
vaccine than those in the lowest quintiles in all years.
Until 2017, vaccination coverage was highest among
Aboriginal and/or Torres Strait Islanders, but the difference
decreased after the implementation of vaccine funding for
all children aged <5 years in 2018 (except in the Northern
Territory). The coverage in any year was similar in boys
and girls, and a patient’s IRSAD did not appear to influ-
ence vaccination coverage as did practice IRSAD. In 2018,
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approximately 20% of children were vaccinated regardless
of their area of residence. On the other hand, children with
comorbidities had a higher vaccination coverage than their
peers in all years, especially in 2018, when the coverage
increased 18 percentage points compared to 2017, while
among those without comorbidities it increased less than
15 percentage points (Table 1).
Figures 1 and 2 analyze in detail the main changes in
influenza vaccination coverage between 2017 and 2018 (i.e.
when funding vaccines were made available in most states)
according to state and practice IRSAD quintiles. The
Northern Territory continued to have the lowest coverage
in 2018, while in Western Australia coverage was less than
two percentage points higher than in 2017. Vaccination
coverage among children attending practices located in
the top IRSAD quintile (i.e. the most advantaged areas)
was 17 percentage points higher than in 2017, while
among practices in the bottom quintile the difference was
of 11 percentage points, reinforcing disparities between
practices in these areas.
Discussion
The study aimed to identify, using de-identified individual
patient electronic medical records from a general practice
database, influenza vaccination coverage in children aged
<5 years and vaccination patterns related to practice and
patient’s characteristics before and after the implementation
of state-funded vaccines. Three main findings can be high-
lighted based on our results. First, vaccination coverage was at
least four times higher in 2018 than previous years in most
Australian states, except Western Australia and the Northern
Territory. Second, patients attending practices in the wealth-
iest areas have the highest vaccination coverage in all years
and they benefited most from this state-funding program.
Finally, children with comorbidities continued to have higher
vaccination coverage than their peers, but the same pattern
was not observed among Aboriginal and/or Torres Strait
Islander children.
Our results showed that coverage was markedly higher in
2018 (~20%) compared to previous years (5%), corroborating
Table 1. Influenza vaccine coverage among ‘active’ patientsa aged < 5 years according to practice and patient’s characteristics. Australia,
2015–2018.
Sample Vaccination Coverage (%)
Distribution (%) 2015 2016 2017 2018
Variable N = 196,520 n = 72,252 n = 81,648 n = 96,282 n = 119,806
Practice characteristicsb
State
New South Wales 35.3 4.0 3.6 4.0 23.9
Victoria 22.3 2.4 2.6 4.4 19.4
Queensland 15.1 3.3 3.7 3.9 17.0
Western Australia 14.5 7.1 7.1 9.7 11.2
Tasmania 7.1 2.7 2.6 5.4 23.4
South Australia 2.0 5.2 3.2 3.9 15.1
Australian Capital Territory 2.4 3.6 3.7 5.9 27.9
Northern Territory 1.3 1.2 1.5 3.3 5.4
Rurality
Major cities 67.1 3.8 3.8 5.3 18.9
Inner regional 20.9 3.7 3.3 4.4 22.5
Outer regional/Remote 12.0 5.0 5.1 5.2 18.4
IRSAD Quintile
Very high 30.2 4.7 4.7 6.1 23.5
High 18.8 3.9 4.0 5.7 21.7
Middle 23.0 4.0 3.9 5.1 19.2
Low 13.4 3.0 3.2 4.0 16.0
Very Low 14.5 2.6 2.2 2.7 13.1
Patient’s characteristicsc
Gender
Male 51.5 3.8 3.9 5.1 19.2
Female 48.5 3.9 3.9 5.1 20.0
Aboriginal/Torres Strait Islander
No 71.8 3.8 3.8 5.2 20.0
Yes 4.5 6.5 5.7 7.1 19.0
Not recorded 23.6 3.5 3.7 4.5 18.4
IRSAD Quintile
Very high 27.4 3.8 4.0 5.0 19.5
High 20.2 4.2 3.6 5.0 19.1
Middle 22.8 3.7 4.1 5.9 21.2
Low 15.0 3.9 3.6 4.9 19.6
Very Low 14.6 3.6 3.5 4.3 18.0
Comorbiditiesd
No 95.0 3.6 3.6 4.9 19.3
Yes 5.0 6.8 7.5 9.8 27.8
Total 100 3.9 3.9 5.1 19.6
aAt least three consultations in any two consecutive years from 2015 to 2018.
bLogistic regression models with all variables (practice characteristics) mutually adjusted.
cLogistic regression models adjusted for gender and practice characteristics.
dComorbidities include: cardiac disease, diabetes and severe asthma.
IRSAD: Index of Relative Socio-economic Advantage and Disadvantage.
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data from the AIR for New South Wales (changing from 5% to
25% in the same period).19 According to the mentioned report
and other studies, to maintain a higher coverage, influenza
vaccination should continue to be funded for all children aged
6 months to 5 years, and strategies should also include providers
to enhance knowledge and awareness on the vaccine, as a direct
recommendation from a health professional has been associated
with a higher likelihood of being vaccinated.19,28,29 A study
performed in the United Kingdom (UK) also found a large
increase in influenza vaccination after the introduction of
a universal vaccination policy for all children aged 2–4 years.
According to that study, the vaccination uptake in the UK
changed from 1% in 2012–2013 to more than 30% in
2014–2015 among children without comorbidities.30
Western Australia and the Northern Territory were the only
two states in our study with less pronounced changes from 2017
to 2018. These findings can be explained by the fact thatWestern
Australia has already funded influenza vaccine for all children
since 2008.17 This may also explain why it had the highest
coverage from 2015 to 2017 among all states and territories. It
is noted, however, that in 2018 the coverage inWestern Australia
(11%) was lower compared to the other states (15–28%, except
by the Northern Territory). This finding suggests that coverage
in other states could decrease over time without appropriate
promotional vaccine strategies, as the state-funding program
may be undermined by the lack of incentive payments.19 On
the other hand, the Northern Territory showed the lowest vac-
cination coverage over the period, and it is probably related to
the funding being started in 2019.17 Nevertheless, a subtle
increase was observed from 2017, probably because of a higher
influenza activity identified in Australia in that year,26 which
may have increased awareness among the community. Unlike
other states, where community health services deliver only 7% of
vaccinations, in the Northern Territory approximately 47% of
vaccinations are administered in this setting.18 In this sense,
results from this jurisdiction should be analyzed with caution,
especially because more than 25% of its population is Aboriginal
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Figure 1. Influenza vaccination coverage among children aged < 5 years in all Australian jurisdictions in 2017 and 2018.
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One of the most important determinants of vaccination
coverage in our study was practice IRSAD. Children from
practices located in the wealthiest areas had higher coverage
than those in the poorest areas before and after the imple-
mentation of the free-vaccine scheme. Moreover, the former
seemed to benefit most from the funding, as the increase in
coverage from 2017 to 2018 was greater among patients from
these practices than those in the poorest areas, increasing
absolute disparities. This relationship was not evident when
analyzing patient’s socioeconomic level (IRSAD quintile),
which suggests that interventions to improve vaccination
coverage would get a greater benefit from promotional cam-
paigns targeting practices and GPs in low socioeconomic
areas.
We identified a similar vaccination coverage in boys and girls,
and this finding is consistent with reports from the UK,30
China31 and Australia.32 On the other hand, vaccination cover-
age between 2015 and 2017 was slightly higher among
Aboriginal and/or Torres Strait Islander children, and similar
figures were reported in a study conducted in New South
Wales.19 Influenza vaccine has been nationally-funded for
these groups since 2015 because of their higher vulnerability to
respiratory illnesses and influenza-related hospitalizations.7,33
However, the increase in vaccination coverage in 2018 reduced
the differences between Indigenous (19%) and non-Indigenous
children (20%), with similar results being identified in the study
from New South Wales (26% and 25%, respectively).19 These
findings should be interpreted cautiously, as these groups are
more likely to be vaccinated at Community and Indigenous
Health Services rather than in general practices.18
Considering that the AIR still has several limitations in
reporting influenza vaccination (e.g. lack of incentive pay-
ments, technical problems in the recording process) and sur-
veys are expensive and may overestimate vaccination
coverage,20 the use of general practice data may be a simple
and low-cost method to monitor annual influenza vaccination
coverage in children. The study strengths include its very
large sample of Australian patients, from all jurisdictions
and socioeconomic areas. Moreover, the database has infor-
mation on the whole medical history of each patient, so it is
possible to identify comorbidities and any other relevant
medical information.21
Despite its strengths, the study is not free of limitations.
Because of ethical restrictions, MedicineInsight only provides
the age in years. Therefore, children under six months (i.e. with
no recommendation for influenza vaccination) are included in
the study, which may have underestimated coverage estimates.
However, it is unlikely that associations with practice or patient’s
characteristics were affected by this limitation. Second, the data-
base is populated during the encounters by GPs or registered
nurses, and depending on the practice routine or burden, data
can have its accuracy and completeness compromised. However,
we used algorithms for data extraction including medical codes
and ‘free’ text in a systematic process and considering different
fields to increase data quality.34 Finally, despite most vaccina-
tions are given in Australian general practice (81%),18 some are
administered in Community and Indigenous Health Services,
local councils or pharmacies, which are not captured by
MedicineInsight.
In conclusion, free access to influenza vaccination has
increased the coverage among children aged <5 years. The
higher coverage in children with comorbidities indicates GPs
and/or parents are aware of the benefits of vaccination among
these children. Interventions to promote increased vaccina-
tion coverage should target practices or GPs in low socio-
economic areas, as practice/GP location was identified as an
important determinant of vaccine coverage. Finally, promo-
tional and educational strategies should be placed in practice
to maintain higher influenza vaccination coverage over time,
as the lack of incentive payments might undermine the ben-
efits of this funded program.
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